Benitec Biopharma
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3940 Trust Way, Hayward, California, 945...Phone Number
(510) 780-0634Website
www.benitec.comRevenue
$7.4 MillionStock Symbol
BNTCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Benitec Biopharma
Benitec Biopharma Ltd is an Australian biotechnology company founded in 1995. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference technology.Explore more
Benitec Biopharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Benitec Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Benitec Biopharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Benitec Biopharma had a recent Job posting/layoffs
Benitec Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Benitec Biopharma launches new products
Funding: Get notified immidiatlly once Benitec Biopharma has new funding data
Earning: See what the market has to say on Benitec Biopharma recently announced quarterly report
Check if Benitec Biopharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Benitec Biopharma
Recommended Actions
Find VP level buyers at Benitec Biopharma
Find more new buyers
Compare Similar Companies to Benitec Biopharma
Compare insights from companies similar to Benitec Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Benitec Biopharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Benitec Biopharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Benitec Biopharma.
Benitec Biopharma financials insights
Gather financial insights about Benitec Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$13.8M
2024
Share Placement
$40M
Benitec Biopharma Tech Stack
A closer look at the technologies used by Benitec Biopharma
Most Recent Scoops
Earnings
Earnings, Finance
Award
Benitec Biopharma has been granted Fast Track designation by the FDA.
Pharmaceuticals
Project
Benitec Biopharma has noted that its first-in-human study design is identical to Option A in the FDA's September 2023 guidance document for pivotal study design for cell and gene therapies for rare diseases.
Pharmaceuticals, Clinical Operations, Regulations
Event
anticipates presenting additional clinical data from both low dose and high dose cohorts in the back half of the year, potentially at World Muscle, ESGCT, or similar conferences.
Medical Research, Clinical Operations
Project
Medical Research, Clinical Operations
Benitec Biopharma News & Media
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 PatientBenitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highBenitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burdenBenitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026-
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Benitec Biopharma
Sign Up For FreeTo access detailed company insights
Benitec Biopharma Ltd is an Australian biotechnology company founded in 1995. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference technology.... Read More
